Wow!

The Aethlon ADAPT^TM System

The Aethlon ADAPT^TM system is an adaptive
dialysis-like affinity platform technology that provides the foundation for an
entirely new class of therapeutics that target the selective clearance of
harmful agents from the entire circulatory system. Therapies that evolve from
the Aethlon ADAPT^TM system overcome the historic limitation of extracorporeal
strategies that indiscriminately adsorb or remove particles solely by molecule
size. In function, our device platform allows the immobilization of single or
multiple affinity drug agents in the outer-capillary space of plasma membrane
technologies as a means to provide rapid real-time clearance of corresponding
targets without adding drug toxicity or interaction risks to established
therapies. Beyond providing a novel regulatory and commercialization pathway for
affinity drug agents, Aethlon ADAPT^TM therapies can be implemented for use within
the global infrastructure of dialysis machines and CRRT systems already located
in hospitals and clinics.
At present, the Aethlon ADAPT^TM product
pipeline includes the Aethlon Hemopurifier® to address infectious disease and
cancer; HER2osome^TM to target HER2+ breast cancer, and a medical device being developed
under a $6.8 million contract with the Defense Advanced Research Projects Agency
(DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and
civilians. As we advance our current pipeline of therapies toward market, we
plan to further leverage our ADAPT^TM system to generate new revenue sources
through future government contracts or grants, and collaborations with
organizations representing the pharmaceutical, biotechnology and medical device
industry.